NCT07314164 Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
| NCT ID | NCT07314164 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ipsen |
| Condition | Neuroendocrine Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-12-17 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2025-12-17 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs). These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow. The study will take place in regular hospitals and clinics in Germany and Austria. It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life. This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Eligibility Criteria
Inclusion Criteria: Participants can join the study if they meet all of the following conditions: * Are 18 years or older and able to give informed consent. * Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study. * Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET). * Have already received at least one prior systemic therapy, other than somatostatin analogues. * Have signed a written informed consent form. Exclusion Criteria: Participants cannot join the study if: * They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study. * They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Contact & Investigator
Ipsen Medical Director
STUDY DIRECTOR
Ipsen
Frequently Asked Questions
Who can join the NCT07314164 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neuroendocrine Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07314164 currently recruiting?
Yes, NCT07314164 is actively recruiting participants. Contact the research team at clinical.trials@ipsen.com for enrollment information.
Where is the NCT07314164 trial being conducted?
This trial is being conducted at Graz, Austria, Linz, Austria, Vienna, Austria, Aschaffenburg, Germany and 11 additional locations.
Who is sponsoring the NCT07314164 clinical trial?
NCT07314164 is sponsored by Ipsen. The principal investigator is Ipsen Medical Director at Ipsen. The trial plans to enroll 150 participants.